Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study

PURPOSE: High‐dose methotrexate (HD‐MTX)-based chemotherapy regimen is the first-line treatment of primary central nervous system lymphoma (PCNSL). At present, doses of MTX in the range of 3.5–8 g/m(2) are frequently used. However, the optimal dose of methotrexate for PCNSL remains controversial. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Ma, Jingjing, Ma, Yan, Lin, Zhiguang, Kang, Hui, Chen, Bobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349527/
https://www.ncbi.nlm.nih.gov/pubmed/34377030
http://dx.doi.org/10.2147/CMAR.S322467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349527/
https://www.ncbi.nlm.nih.gov/pubmed/34377030
http://dx.doi.org/10.2147/CMAR.S322467

Ejemplares similares